GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLF) » Definitions » 3-Year EBITDA Growth Rate

OPHLF (Ono Pharmaceutical Co) 3-Year EBITDA Growth Rate : 17.50% (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Ono Pharmaceutical Co 3-Year EBITDA Growth Rate?

Ono Pharmaceutical Co's EBITDA per Share for the three months ended in Sep. 2024 was $0.44.

During the past 12 months, Ono Pharmaceutical Co's average EBITDA Per Share Growth Rate was -19.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ono Pharmaceutical Co was 45.10% per year. The lowest was -17.10% per year. And the median was 2.00% per year.

Competitive Comparison of Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.


Ono Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ono Pharmaceutical Co  (OTCPK:OPHLF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ono Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ono Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ono Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ono Pharmaceutical Co Ltd (OTCPK:OPHLF) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
TSE:4151 TSE:4536 TSE:4552 TSE:4882 TSE:4578 TSE:4503 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4568
Traded in Other Exchanges
OPHLY:USA 4528:Japan ON4:Germany
Address
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, JPN, 541-8564
Website
http://www.ono.co.jp
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. It maintains a world-wide business in specialty pharmaceuticals. The company breaks out its revenue of goods and products into eight segments. The vast majority of Ono's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of Ono's sales are generated in Japan, followed by the rest of Asia and Europe.